Literature DB >> 15913963

Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia.

Georges M Gharabawi1, Cynthia A Bossie, Robert A Lasser, Ibrahim Turkoz, Stephen Rodriguez, Guy Chouinard.   

Abstract

Assessing tardive dyskinesia (TD) has been complicated by the use of different research criteria and rating scales. We studied concordance between two commonly used scales, the Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS), to study interscale concordance and criteria to define TD. Patients with schizophrenia or schizoaffective disorder (N = 374) were rated at baseline with both scales. Linear and logistic regression models explored relationships between scale ratings and mapped scores for corresponding items. TD was defined as at least mild in > or = 2 anatomical areas, or moderate or greater symptoms in > or = 1 area at baseline. Logistic regression was used to find simplified criteria for predicting AIMS-defined TD by ESRS scores. There was a strong association on corresponding item ratings. "Mild" was defined as AIMS score of 2 and ESRS 2 or 3, and "moderate or greater" as AIMS score > or = 3 and ESRS > or = 4. Using these criteria, there was 96.0% (359/374) agreement between AIMS- and ESRS-defined TD cases. The ESRS Clinical Global Impressions of severity of dyskinesia (CGI-SD) best predicted AIMS-defined TD. An ESRS CGI-SD > or = 4 (95% CI: 3.61, 4.76) was associated with > or = 95% probability of AIMS-defined TD. High concordance between the scales for dyskinesia scores was found. Findings suggest that the ESRS CGI-SD score can serve as a simplified criterion for identifying AIMS-defined TD, and may be a useful tool for future research-based TD analyses, when occurring in the context of a full movement disorder assessment.

Entities:  

Mesh:

Year:  2005        PMID: 15913963     DOI: 10.1016/j.schres.2005.03.008

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  16 in total

1.  Structural analysis of the basal ganglia in schizophrenia.

Authors:  Daniel Mamah; Lei Wang; Deanna Barch; Gabriel A de Erausquin; Mokhtar Gado; John G Csernansky
Journal:  Schizophr Res       Date:  2006-10-30       Impact factor: 4.939

2.  Evaluation of health promotion programmes in severe mental illness: theory and practice.

Authors:  Fenneke M van Hasselt; Paul F M Krabbe; Maarten J Postma; Anton J M Loonen
Journal:  Int J Methods Psychiatr Res       Date:  2014-12-09       Impact factor: 4.035

3.  The Harms of Antipsychotic Drugs: Evidence from Key Studies.

Authors:  Thomas J Moore; Curt D Furberg
Journal:  Drug Saf       Date:  2017-01       Impact factor: 5.606

4.  Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol.

Authors:  Ina Giegling; Beatrice Balzarro; Stefano Porcelli; Martin Schäfer; Annette M Hartmann; Marion Friedl; Bettina Konte; Philipp Krämer; Hans-Jürgen Möller; Diana De Ronchi; Hans H Stassen; Alessandro Serretti; Dan Rujescu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-08-15       Impact factor: 5.270

Review 5.  Interrelations between psychiatric symptoms and drug-induced movement disorder.

Authors:  Guy Chouinard
Journal:  J Psychiatry Neurosci       Date:  2006-05       Impact factor: 6.186

6.  Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth.

Authors:  Tamara Pringsheim; Asif Doja; Stacey Belanger; Scott Patten
Journal:  Paediatr Child Health       Date:  2011-11       Impact factor: 2.253

7.  [Not Available].

Authors:  Tamara Pringsheim; Asif Doja; Stacey Belanger; Scott Patten
Journal:  Paediatr Child Health       Date:  2012-10       Impact factor: 2.253

8.  Handwriting analysis indicates spontaneous dyskinesias in neuroleptic naïve adolescents at high risk for psychosis.

Authors:  Derek J Dean; Hans-Leo Teulings; Michael Caligiuri; Vijay A Mittal
Journal:  J Vis Exp       Date:  2013-11-21       Impact factor: 1.355

9.  Impact of a pharmacist-driven tardive dyskinesia screening service.

Authors:  Niyati Butala; Andrew Williams; Jamie Kneebusch; Melissa Mitchell
Journal:  Ment Health Clin       Date:  2021-07-16

10.  No association of a set of candidate genes on haloperidol side effects.

Authors:  Antonio Drago; Ina Giegling; Martin Schäfer; Annette M Hartmann; Hans-Jürgen Möller; Diana De Ronchi; Hans H Stassen; Alessandro Serretti; Dan Rujescu
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.